ada standards of care 2025 glp-1 receptor agonists recommendations The New ADA/EASD Type 1 Diabetes Adult Guidelines 2025-ADA-SOC-Slide-Deck-all-recommendations-FINAL-12-9-24.pptx

95% CI 0.89, 0.96) and all-cause mortality rate (HR 0.70

There is no argument that the drugs are much more potent and faster acting than your bodies natural GLP-1 hormones

A dual GIP/GLP-1 agonist studied in metabolic research

Since most glucose-dependent insulinotropic polypeptide (GIP) receptor: glucagon-like peptide- 1 receptor (GLP- 1) receptor: glucagon receptor triagonists compete in efficacy with bariatric surgery, the success of these agents in preclinical models and clinical trials suggests a bright future for multi-agonists in the treatment of metabolic diseases

manufactured in cGMP-certified facilities, third-party tested for purity, and non-GMO, gluten-free, with zero artificial additives or fillers

This may help you feel fuller sooner, reduce hunger, and lower overall calorie intake